Radiosensitization using hydrogen peroxide in patients with cervical cancer

Hu,Rong; Saito,Anneyuko I.; Mitsuhashi,Taira; Inoue,Tatsuya; Ota,Tsuyoshi; Ujihira,Takafumi; Yoshida,Koyo; Sasai,Keisuke

doi:10.3892/mco.2021.2304

Radiosensitization using hydrogen peroxide in patients with cervical cancer

Authors:
- Rong Hu
- Anneyuko I. Saito
- Taira Mitsuhashi
- Tatsuya Inoue
- Tsuyoshi Ota
- Takafumi Ujihira
- Koyo Yoshida
- Keisuke Sasai
View Affiliations

Affiliations: Department of Radiation Oncology, Juntendo University Faculty of Medicine, Bunkyo, Tokyo 113‑8421, Japan, Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu, Chiba 279‑0021, Japan
Published online on: May 23, 2021 https://doi.org/10.3892/mco.2021.2304
Article Number: 142

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to analyze the feasibility and safety of radiosensitization using hydrogen peroxide for cervical cancer. In superficial tumors, breast cancer and hepatocellular carcinoma, the safety and effectiveness of radiosensitization has been reported; to the best of our knowledge, however, there are no reports on cervical cancer. A total of 20 patients with cervical cancer were recruited. Inclusion criteria were as follows: Patients who required radical external beam radiotherapy (RT); ineligible for or refused brachytherapy; age, ≥20 years; no hematogenous metastasis; Eastern Cooperative Oncology Group Performance Status up to 2; and had not undergone prior treatment. Hydrogen peroxide was used twice a week in combination with RT. A 3% hydrogen peroxide solution‑soaked gauze was inserted into the vagina during RT. A total of 45 Gy was delivered in 25 fractions to the whole pelvis with a boost of 10 Gy in 5 fractions if pelvic or para‑aortic metastatic lymph nodes were observed. Ultimately, 18 patients were evaluated. Among the 17 patients (excluding one patient with tumor in situ), the one‑ and two‑year overall survival rates were both 90% in patients with stage I/II and 86% in stage III/IV cervical cancer. The adverse events were well tolerated with no severe acute or late adverse events. Although limited by small sample size, short observation time and low radiation dose, the present study demonstrated that radiosensitization treatment may be an option for patients who cannot undergo brachytherapy. The study was retrospectively registered at the university hospital medical information network center (no. UMIN000039045) on January 6, 2020.

View Figures

View References

1	Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 13:139–168. 1994.PubMed/NCBI View Article : Google Scholar
2	Weinmann M, Belka C and Plasswilm L: Tumor hypoxia: Impact on biology, prognosis and treatment of solid malignant tumors. Oncology. 27:83–90. 2004.PubMed/NCBI View Article : Google Scholar
3	Wang H, Jiang H, Van De Gucht M and De Ridder M: Hypoxic Radioresistance: Can ROS be the key to overcome it? Cancers (Basel). 11(112)2019.PubMed/NCBI View Article : Google Scholar
4	Ogawa Y: Paradigm shift in radiation biology/radiation oncology-exploitation of the ‘H₂O₂ Effect’ for radiotherapy using low-LET (Linear Energy Transfer) radiation such as X-rays and high-energy electrons. Cancers (Basel). 8(28)2016.PubMed/NCBI View Article : Google Scholar
5	Nimalasena S, Gothard L, Anbalagan S, Allen S, Sinnett V, Mohammed K, Kothari G, Musallam A, Lucy C, Yu S, et al: Intratumoural hydrogen peroxide with radiotherapy in locally advanced breast cancer: Results from a phase I clinical trial. Int J Radiat Oncol Biol Phys. 108:1019–1029. 2020.PubMed/NCBI View Article : Google Scholar
6	KORTUC Phase II - Intra-tumoural radiation sensitizer in patients with locally advanced/recurrent breast cancer. https://clinicaltrials.gov/ct2/show/NCT03946202. Accessed September 12, 2020.
7	Cervix Uteri. Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf. Accessed March 1 2021.
8	CERV-6. NCCN Guidelines Version 1.2021Cervical CancerNCCN Evidence Blocks™. https://www.nccn.org/professionals/physician_gls/pdf/cervical_blocks.pdf. Accessed March 1, 2021.
9	Banerjee R and Kamrava M: Brachytherapy in the treatment of cervical cancer: A review. Int J Womens Health. 6:555–564. 2014.PubMed/NCBI View Article : Google Scholar
10	Japanese Structure Survey of Radiation Oncology in 2015 (First Report). https://www.jastro.or.jp/medicalpersonnel/data_center/cat6/cat/2015.html. Accessed 12 September 2020.
11	Ogawa Y, Ue H, Tsuzuki K, Tadokoro M, Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, et al: New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 19:1389–1394. 2008.PubMed/NCBI
12	Ogawa Y, Kubota K, Ue H, Tadokoro M, Matsui R, Yamanishi T, Hamada N, Kariya S, Nishioka A, Nakajima H, et al: Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 39:553–560. 2011.PubMed/NCBI View Article : Google Scholar
13	Aoyama N, Ogawa Y, Yasuoka M, Takahasi M, Iawasa H, Miyatake K, Yamanishi T, Hamada N, Tamura T, Kobayashi K, et al: Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi oxydol-radiation therapy for unresectable carcinomas) in patients with recurrent breast cancer. Oncol Lett. 12:29–34. 2016.PubMed/NCBI View Article : Google Scholar
14	Aoyama N, Ogawa Y, Yasuoka M, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, et al: Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane. Oncol Lett. 13:69–76. 2017.PubMed/NCBI View Article : Google Scholar
15	Nishioka A, Ogawa Y, Miyatake K, Tadokoro M, Nogami M, Hamada N, Kubota K, Kariya S, Kohsaki T, Saibara T, et al: Safety and efficacy of imageguided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Oncol Lett. 8:404–408. 2014.PubMed/NCBI View Article : Google Scholar
16	Ogawa Y, Kubota K, Aoyama N, Yamanishi T, Kariya S, Hamada N, Nogami M, Nishioka A, Onogawa M and Miyamura M: Non-surgical breast-conserving treatment (KORTUC-BCT) using a new radiosensitization method (KORTUC II) for patients with stage I or II breast cancer. Cancers (Basel). 7:2277–2289. 2015.PubMed/NCBI View Article : Google Scholar
17	3.2Mechanism of Causing Effects on Human Body. BOOKLET to Provide Basic Information Regarding Health Effects of Radiation (1st edition). Ministry of the Enviroment Government of Japan. https://www.env.go.jp/en/chemi/rhm/basic-info/1st/ Assecced March 3, 2021.
18	Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National cancer institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed September 12, 2020.
19	Eisenhauer EA, Therasse P, Bogaerts J, Schawartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
20	CERV-G. NCCN Guidelines Version 1.2021Cervical CancerNCCN Evidence BlocksTM. https://www.nccn.org/professionals/physician_gls/pdf/cervical_blocks.pdf. Accessed March 1, 2021.
21	Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshikin LR, Viswanathan AN and Gaffney DK: Cervical cancer: A global health crisis. Cancer. 123:2404–2412. 2017.PubMed/NCBI View Article : Google Scholar
22	Yang J, Cai H, Xiao ZX, Wang H and Yang P: Effect of radiotherapy on the survival of cervical cancer patients: An analysis based on SEER database. Medicine (Baltimore). 98(e16421)2019.PubMed/NCBI View Article : Google Scholar
23	Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Nagan HY and Pecorelli S: Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 95 (Suppl 1):S43–S103. 2006.PubMed/NCBI View Article : Google Scholar
24	Karlsson J, Dreifaldt A, Mordhorst LB and Sorbe B: Difference in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy. 16:133–140. 2017.PubMed/NCBI View Article : Google Scholar
25	Barraclough LH, Swindell R, Livsey JE, Hunter RD and Davidson SE: External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys. 71:772–778. 2008.PubMed/NCBI View Article : Google Scholar
26	Matsuura K, Okabe T, Fujita K, Tanimoto H, Akagi Y and Kagemoto M: Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy. J Radiat Res. 53:900–905. 2012.PubMed/NCBI View Article : Google Scholar
27	Ito K, Shimizuguchi T and Karasawa K: Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy. Jpn J Clin Oncol. 49:270–275. 2019.PubMed/NCBI View Article : Google Scholar
28	Park HC, Shimizu S, Yonesaka A, Tsuchiya K, Ebina Y, Taguchi H, Katoh N, Kinoshita R, Ishikawa M, Sakuragi N and Shirato H: High dose three-dimensional conformal boost using the real-time tumor tracking radiotherapy system in cervical cancer patients unable to receive intracavitary brachytherapy. Yonsei Med J. 51:93–99. 2010.PubMed/NCBI View Article : Google Scholar
29	Saibishkumar EP, Patel FD, Sharma SC, Karunanidhi G, Sankar AS and Mallick I: Results of external-beam radiotherapy alone in invasive cancer of the uterine cervix: A retrospective analysis. Clin Oncol (R Coll Radiol). 18:46–51. 2006.PubMed/NCBI View Article : Google Scholar
30	Yoshida K, Yamazaki H, Kotsuma T, Takenaka T, Ueda MM, Miyake S, Tsujimoto Y, Masui K, Yoshioka Y, Sumida I, et al: Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size? Brachytherapy. 15:57–64. 2016.PubMed/NCBI View Article : Google Scholar
31	Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP and Hsueh S: Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 60:249–257. 2004.PubMed/NCBI View Article : Google Scholar